Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.45 |
| ▸ | KDM4A | O75164 | 3/20 | 0.45 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.45 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.42 |
| ▸ | KDM5A | P29375 | 2/20 | 0.42 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.42 |
| ▸ | ASPH | Q12797 | 1/20 | 0.42 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | KDM6B | O15054 | 2/20 | 0.38 |
| ▸ | KDM4D | Q6B0I6 | 2/20 | 0.38 |
| ▸ | KDM6A | O15550 | 1/20 | 0.38 |
| ▸ | TET3 | O43151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30530504 | 1.00 | KDM4E (0.47) | KDM4EL3MBTL1KDM4AEGLN1RAB9A | |
| SCHEMBL16965398 | 0.82 | LCK (0.45) | KDM4EL3MBTL1KDM4AEGLN1RAB9A | |
| SCHEMBL27012539 | 0.79 | KDM4E (0.36) | KDM4EL3MBTL1KDM4CKMT2ATP53 | |
| SCHEMBL25097311 | 0.77 | KDM4E (0.46) | KDM4EL3MBTL1KDM4AEGLN1RAB9A | |
| SCHEMBL30217795 | 0.77 | KDM4E (0.46) | KDM4EL3MBTL1KDM4AEGLN1RAB9A | |
| SCHEMBL10464797 | 0.76 | CYP1A2 (0.54) | KDM4EL3MBTL1KDM4AEGLN1RAB9A | |
| SCHEMBL28512682 | 0.75 | KDM4E (0.57) | KDM4EL3MBTL1KDM4AEGLN1RAB9A | |
| SCHEMBL15129590 | 0.75 | KDM4E (0.42) | KDM4EL3MBTL1KDM4AEGLN1RAB9A | |
| SCHEMBL4519716 | 0.75 | KDM4E (0.68) | KDM4EL3MBTL1KDM4AEGLN1RAB9A | |
| Hydrochloric Acid SCHEMBL15328531 | 0.74 | KDM4E (0.66) | KDM4EL3MBTL1KDM4AEGLN1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20230372496-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | C4 THERAPEUTICS, INC. (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230372496-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | C4 THERAPEUTICS, INC. (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230372496-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | C4 THERAPEUTICS, INC. (US) | 2023-11-23 | — | — | US | disclosed |
| CN-116723839-A | Tricyclic heterobifunctional compounds for degrading target proteins | C4医药公司 | 2023-09-08 | — | — | CN | disclosed |
| EP-4228625-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | C4 Therapeutics, Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-4228624-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C4 Therapeutics, Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| CN-116457339-A | Tricyclic compounds degrading novel substrates for medical treatment | C4医药公司 | 2023-07-18 | — | — | CN | disclosed |
| WO-2022081928-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | C4 THERAPEUTICS, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022081928-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | C4 THERAPEUTICS, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022081927-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C4 THERAPEUTICS, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022081927-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C4 THERAPEUTICS, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230372496-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | CRBN, CDR2, MDM2 | KDM4E 2875/4885L3MBTL1 888/4885KDM4A 2110/4885 |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | NFATC1, CTSS, MMP12 | KDM4E 791/4885L3MBTL1 3664/4885KDM4A 377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.